Online inquiry

IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6375MR)

This product GTTS-WQ6375MR is a type of mRNA modified with 5-Methyl-CTP, which ecodes the monoclonal antibody that targets Factor IX substitute gene. The antibody can be applied in Hemophilia B research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000133.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2158
UniProt ID P00740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ6375MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8141MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HH1
GTTS-WQ13606MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA R1450
GTTS-WQ14193MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-910
GTTS-WQ3258MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ART621
GTTS-WQ13022MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ4919MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ13946MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-2810
GTTS-WQ1822MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AFD Anti-fD
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW